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Background: Patients with metastatic pancreatic cancer often have a detriment in health-related quality of life (HRQoL). In the
randomized, double-blind, phase III POLO trial progression-free survival was significantly longer with maintenance olaparib, a
poly(ADP-ribose) polymerase inhibitor, than placebo in patients with a germline BRCA1 and/or BRCA2 mutation (gBRCAm) and
metastatic pancreatic cancer whose disease had not progressed during first-line platinum-based chemotherapy. The
prespecified HRQoL evaluation is reported here.
Patients and methods: Patients were randomized to receive maintenance olaparib (300 mg b.i.d.; tablets) or placebo. HRQoL
was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item
module at baseline, every 4 weeks until disease progression, at discontinuation, and 30 days after last dose. Scores ranged from
0 to 100; a10-point change or difference between arms was considered clinically meaningful. Adjusted mean change from
baseline was analysed using a mixed model for repeated measures. Time to sustained clinically meaningful deterioration
(TSCMD) was analysed using a log-rank test.
Results: Of 154 randomized patients, 89 of 92 olaparib-arm and 58 of 62 placebo-arm patients were included in HRQoL
analyses. The adjusted mean change in Global Health Status (GHS) score from baseline was <10 points in both arms and there
was no significant between-group difference [2.47; 95% confidence interval (CI)7.27, 2.33; P¼ 0.31]. Analysis of physical
functioning scores showed a significant between-group difference (4.45 points; 95% CI8.75,0.16; P¼ 0.04). There was no
difference in TSCMD for olaparib versus placebo for GHS [P¼ 0.25; hazard ratio (HR) 0.72; 95% CI 0.41, 1.27] or physical
functioning (P¼ 0.32; HR 1.38; 95% CI 0.73, 2.63).
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Conclusions: HRQoL was preserved with maintenance olaparib treatment with no clinically meaningful difference compared
with placebo. These results support the observed efficacy benefit of maintenance olaparib in patients with a gBRCAm and
metastatic pancreatic cancer.
ClincalTrials.gov number: NCT02184195.
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Introduction
Pancreatic cancer is the 13th most common cancer and 7th most
common cause of cancer death worldwide [1]. Patients often pre-
sent with advanced disease with worldwide 5-year survival rates
of 9%, reducing to 3% for metastatic pancreatic cancer [2].
Median progression-free survival (PFS) with standard-of-care
first-line treatments is around 6 months and disease progression
can result in deterioration in health-related quality of life
(HRQoL) [3, 4]. As a consequence, patients with metastatic pan-
creatic cancer have reduced HRQoL due to high emotional bur-
den, symptom burden (in particular pain, fatigue, vomiting and
diarrhoea), and poor prognosis [5–10]. When evaluating the best
treatment option for patients with metastatic pancreatic cancer,
it is important to not only assess survival, which is relatively
short, but also ensure that there are no detrimental effects of
treatment on HRQoL. Indeed, American Society for Clinical
Oncology guidelines on treatment of metastatic pancreatic cancer
recommend that clinicians should proactively discuss quality of
life issues such as pain, fatigue, and loss of appetite, which tend to
be overlooked yet have significant impact on daily life, with their
patients [11].
In the international, randomized, placebo-controlled phase III
POLO trial patients with metastatic pancreatic cancer and a
germline BRCA1 and/or BRCA2 mutation (gBRCAm) whose dis-
ease had not progressed on first-line platinum-based chemother-
apy derived a statistically significant and clinically meaningful
improvement in PFS from maintenance treatment with the
poly(ADP-ribose) polymerase inhibitor olaparib versus placebo
[12]. The aim of maintenance treatment is to prolong PFS, and
ultimately overall survival, delaying the need for subsequent cyto-
toxic chemotherapy. In addition, maintenance treatment should
seek to preserve HRQoL, which may be improved following ef-
fective first-line chemotherapy [13]. First-line treatment with
FOLFIRINOX has been shown to improve overall HRQoL and
lead to a decrease in some symptoms, including pain, for patients
with metastatic pancreatic cancer [13]. A prespecified secondary
objective of the POLO trial was to evaluate the effect of olaparib
on HRQoL, specifically the adjusted mean change from baseline
in Global Health Status (GHS) score using the European
Organisation for Research and Treatment of Cancer Quality of
Life Questionnaire Core 30-item module (EORTC QLQ-C30).
Methods
Patient population and study design
Details of this randomized double-blind, placebo-controlled phase III
trial have been reported previously [12]. Briefly, patients aged 18 years
with histologically or cytologically confirmed pancreatic
adenocarcinoma and a documented deleterious or suspected deleterious
gBRCAm were eligible. Patients had received 16 weeks of continuous
first-line platinum-based chemotherapy for metastatic pancreatic cancer,
although duration was unlimited as long as no evidence of disease pro-
gression was noted by the investigator at randomization. Patients were
randomized in a 3 : 2 ratio to receive maintenance olaparib tablets
(300 mg twice daily) or matching placebo, initiated 4–8 weeks after the
last dose of first-line chemotherapy and continued until objective radio-
logic disease progression (investigator-assessed according to modified
Response Evaluation Criteria in Solid Tumors v1.1) or unacceptable tox-
icity [14]. Crossover to olaparib was not permitted during the trial.
Study outcome measures
A prespecified secondary objective of the POLO study was to assess
HRQoL using the EORTC QLQ-C30 questionnaire. Additional HRQoL
data were collected using the pancreatic cancer specific EORTC QLQ-
PAN26 questionnaire (data not reported here). These questionnaires are
considered appropriate to assess the pancreatic cancer patient experience
[15]. The EORTC QLQ-C30 includes a two-item GHS scale, five multi-
item functioning scales, three multi-item symptom scales, five single-
item symptom scales, and a single-item financial impact scale [16]. Raw
scores were transformed on to a scale ranging from 0 to 100; transformed
scores are reported here. For GHS and functioning scales, a higher score
is indicative of better quality of life whereas for symptom scales a higher
score is indicative of more severe symptoms. A change from baseline of
10 points was predefined as clinically meaningful, based on the pub-
lished literature [17–19]. Assessments were undertaken at baseline, every
4 weeks until disease progression, at discontinuation of study treatment,
and 30 days after last dose. The primary HRQoL end point was adjusted
mean change from baseline in GHS score. Best HRQoL response (im-
provement, no change, or deterioration), the proportion of patients with
a clinically meaningful change (defined as a10-point change from base-
line) and time to sustained clinically meaningful deterioration (TSCMD)
were secondary HRQoL end points. A TSCMD event was defined as a
10-point decrease (GHS and functioning subscales) or increase (symp-
tom subscales) from baseline (or a patient being too ill to complete the
questionnaire) sustained at the next scheduled visit with no response of
‘improved’ or ‘no change’ in between the two visit responses of ‘deterior-
ation’, or death. In addition to the GHS score evaluation, exploratory
analyses of functioning scores (physical, role, cognitive, emotional, and
social) and patient-reported symptoms (pain, fatigue, nausea and vomit-
ing, appetite loss and insomnia) were prespecified. Results from datasets
considered to be most clinically relevant (GHS, physical functioning, and
symptom subscales) are reported here.
Statistical analysis
HRQoL data were analysed in the subset of patients in the intention-to-
treat population who had an evaluable baseline EORTC QLQ-C30 or
QLQ-PAN26 form [patient-reported outcome (PRO) analysis set]. An
evaluable form was defined as one on which at least one subscale baseline
score could be determined.
For the adjusted mean change from baseline in GHS score analysis,
only visits with at least 25% non-missing values in each treatment arm
were included; study treatment discontinuation and 30 days following
last dose of study treatment visits were excluded. The analysis was carried
out using a linear mixed model for repeated measures, adjusted for score
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at baseline, time, and treatment-by-time interaction to estimate the cu-
mulative effect of olaparib versus placebo on GHS. Between-group differ-
ences were compared using adjusted mean estimates for each treatment
group with a between-group difference of10 points defined as clinically
meaningful, based on published literature [17–19]. A change of 10
points from baseline was also predefined as clinically meaningful [17–
19]. TSCMD was analysed by log-rank test [hazard ratio (HR)<1 favours
olaparib] in all patients with a baseline score 10 (GHS and functioning
subscale analyses) or 90 (symptom subscales). HRQoL improvement




Baseline characteristics of randomized patients are reported in
the primary manuscript [12].
Of 154 randomized patients, 89 of 92 who received olaparib
and 58 of 62 who received placebo were included in the PRO ana-
lysis set; the remaining seven patients had missing baseline forms.
HRQoL scores were well-balanced between treatment groups at
baseline with overall high scores for GHS and physical function-
ing scales, and low scores for symptom scales (supplementary
Figure S1, available at Annals of Oncology online).
Questionnaire compliance
The overall compliance rate for EORTC QLQ-C30 was high,
100% at baseline and 96.6% and 94.8% overall in the olaparib
and placebo groups, respectively, based on the PRO analysis set
(supplementary Figure S2, available at Annals of Oncology
online).
Global Health Status
Mean baseline scores for GHS were high compared with those
from other metastatic pancreatic cancer trials [13]; 70.4 in the
olaparib and 74.3 in the placebo group (supplementary Figure
S1A, available at Annals of Oncology online). GHS scores
remained relatively stable over time for both treatment groups
(Figure 1A). There was no statistically significant difference in
overall between-group adjusted mean change from baseline for
GHS score [between-group difference 2.47; 95% confidence
interval (CI) 7.27, 2.33; P¼ 0.31] calculated across the first
6 months of treatment (Figure 2A). The median TSCMD for
GHS score was 21.2 months for olaparib and 6.0 months for pla-
cebo (HR 0.72; 95% CI 0.41, 1.27; P¼ 0.25) (Figure 3). A similar
proportion of patients in each arm reported improvement in
GHS score: 26/89 (29.2%) in the olaparib and 13/58 (22.4%) in
the placebo group (OR 1.43; 95% CI 0.67, 3.15; P¼ 0.36)
(Figure 4).
Physical functioning
Mean baseline physical functioning scores were similarly high in
both treatment groups and improved over time (supplementary
Figure S1A, available at Annals of Oncology online; Figure 1B).
The between-group difference in adjusted mean change from
baseline for physical functioning was 4.45 points (95% CI
8.75, 0.16; P¼ 0.04) (Figure 2A). There was no statistically
significant between-group difference in TSCMD for physical
functioning (medians not reached; HR 1.38; 95% CI 0.73, 2.63;
P¼ 0.32) (Figure 3B). The proportion of patients with best
HRQoL responses of ‘improved’ or ‘deterioration’ for physical
functioning was similar between arms (Figure 4). Analyses of
role, emotional, cognitive and social functioning showed no
between-group differences in adjusted mean change from base-
line of 10-points and no statistically significant differences in
TSCMD between arms.
Symptom subscales
Mean symptom scale scores were low at baseline, reflecting a low
symptom burden (supplementary Figure S1B, available at Annals
of Oncology online). For the symptom scales of fatigue, nausea
and vomiting, and appetite loss between-group differences were
statistically significant in favour of placebo. For fatigue, and nau-
sea and vomiting the between-group difference was <10 points,
whereas for appetite loss the between-group difference was 10.11
points (Figure 2B). There were no between-group differences in
TSCMD for any symptom scores, except for nausea and vomit-
ing, and constipation for which there were significant differences
in favour of placebo (Figure 3B). Best HRQoL responses for
symptom subscales are shown in Figure 4.
Discussion
Metastatic pancreatic cancer, which is the initial diagnosis for
50%–60% of pancreatic cancer patients, has a poor prognosis
[20]. Therefore, treatment should focus not only on prolonging
disease progression or improving survival but should also con-
sider preserving or improving quality of life, because symptoms
such as fatigue, pain, appetite and weight loss, and decreased
functional status all have a detrimental impact on HRQoL for
patients with this disease.
Patients were randomized into the POLO study following a
minimum of 4 months of first-line platinum-based chemother-
apy (although there was no maximum limit to the duration of
platinum-based treatment) and patients whose disease had pro-
gressed during first-line chemotherapy were not eligible for this
maintenance trial. With the exception of alopecia, peripheral
neuropathy and anaemia, toxic effects from previous treatments
must have resolved to grade 1 before randomization [12]. The
majority of patients (84%) had received variants of
FOLFIRINOX, which is known to significantly improve GHS
over the first 6 months of treatment [12, 13]; in the seminal phase
III study FOLFIRINOX improved mean GHS score from 53.8 at
baseline to 68.3 at the end of 6 months of treatment [13]. It is
therefore not surprising that patients in the POLO study had con-
sistently higher baseline GHS and physical functioning scores
and lower symptom severity than the general population of
patients with gastrointestinal cancers, reflecting low disease bur-
den following first-line chemotherapy [21]. The mean GHS score
was 70.4 in the olaparib arm at baseline, consistent with expecta-
tions based on FOLFIRINOX data. Preservation of HRQoL is a
major therapeutic goal in the maintenance setting and further
improvement in comparison with placebo may not be expected.
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Figure 1. Mean change from baseline in EORTC QLQ-C30 scores across timepoints, by treatment group for (A) Global Health Status and
(B) physical functioning scores. A change from baseline of 10 points was predefined as clinically meaningful. Error bars denote 95% confi-
dence intervals.
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Furthermore, standard-of-care chemotherapy agents are often
associated with cumulative treatment-emergent toxicities that
further affect HRQoL and a potential decrease in GHS has been
observed when FOLFIRINOX treatment is continued beyond
6 months [10, 13].
High baseline GHS scores in the POLO study were preserved
with olaparib maintenance treatment and the primary HRQoL
end point (adjusted mean change from baseline) showed no stat-
istically significant or clinically meaningful difference between
the olaparib and placebo groups. Furthermore, median TSCMD
was longer in the olaparib (21.2 months) than the placebo group
(6.0 months), although this difference was not statistically signifi-
cant. This result may be influenced by a higher degree of censor-
ing and smaller number of assessable patients (reflective of earlier
disease progression) in the placebo arm compared with the ola-
parib arm. In addition, the proportion of patients with improved
GHS score was similar in the olaparib (29.2%) and placebo
groups (22.4%).
Evaluation of the physical functioning subscale indicated a sig-
nificant between-group difference in adjusted mean change from
baseline, favouring placebo; however, this difference was not con-
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Figure 2. Overall adjusted mean change from baseline in EORTC QLQ-C30 scores over the first 6 months of treatment (A) Global Health
Status and physical functioning and (B) symptom scales. An adjusted mean change from baseline or between-group difference of 10
points was considered to be clinically meaningful. For each subscale, only visits with at least 25% non-missing values in each treatment arm
were included, therefore analyses cover only the first 6 months of treatment. Error bars denote 95% confidence intervals. *Between-group
differences were considered statistically significant if P<0.05. †For diarrhoea, N¼53. CI, confidence interval; QoL, quality of life.
Annals of Oncology Original article
Volume 30 | Issue 12 | 2019 doi:10.1093/annonc/mdz406 | 1963
threshold [17–19] and high baseline scores were preserved with
olaparib treatment. In addition, there were no clinically meaning-
ful between-group differences in change from baseline for symp-
tom scales, with the exception of appetite loss, which showed a
clinically meaningful difference favouring placebo. The notable
findings in appetite loss scores appear to be driven by an im-
provement of these symptoms in the placebo group, since appe-
tite loss scores remained low and stable over time in the olaparib
group. Furthermore, appetite loss is a recognised treatment-
related symptom of olaparib [22]. Lower symptom scores indi-
cate reduced symptom burden and all other symptom scores
remained low during maintenance olaparib treatment.
A 10-point change from baseline in EORTC QLQ-C30 score
was predefined as clinically meaningful, based on the published
literature. A study designed to determine the significance to
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Figure 3. Time to sustained clinically meaningful deterioration (A) Kaplan–Meier plot for EORTC QLQ-C30 Global Health Status and (B) Forest
plot for EORTC QLQ-C30 Global Health Status, physical functioning and symptom scales. Patients with baseline scores 10 were included in
analyses of Global Health Status and physical functioning scores; patients with baseline scores 90 were included in analyses of symptom
scores. Patients who had not had a TSCMD event or who had a TSCMD event after two or more missed HRQoL assessment visits were cen-
sored at the time of their last HRQoL assessment where the respective score could be evaluated; however, patients were not censored if
they had two missing visits between two evaluable HRQoL assessments (and the outcome of the second assessment was not deterioration)
and subsequently went on to show sustained clinically meaningful deterioration. CI, confidence interval.
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baseline in EORTC QLQ-C30 score generally reflected a change
in quality of life that was ‘moderately’ or ‘very much’ better or
worse [17] and was consistent with results from a systematic re-
view of randomized controlled trials in various cancer settings,
which demonstrated that a mean difference of 10–15 points in
GHS score represented a medium effect size that was likely to be
clinically relevant [18]. This 10-point threshold has been adopted
for other studies based on EORTC QLQ-C30 data, including
those in the pancreatic cancer setting, suggesting that it is an ap-
propriate and generally accepted definition [19, 23, 24]; however,
it is worth noting that at the time the POLO study was designed,
there was no precedent for defining a clinically meaningful
change in the maintenance setting.
In the POLO study, patients in the olaparib arm derived a stat-
istically significant and clinically meaningful PFS benefit com-
pared with placebo and a trend towards increased time to second
progression was observed, suggesting the treatment benefit may
be maintained through subsequent lines of therapy [12]. In add-
ition, time to first subsequent therapy was significantly delayed in
the olaparib arm [25]. Patients discontinued study treatment at
disease progression and were only followed for HRQoL for
1 month after this point, therefore follow-up for HRQoL was
considerably shorter in the placebo arm and the impact of disease
progression, or any subsequent treatments, on HRQoL was not
taken into account. Adjusted mean change from baseline analyses
only included visits at which 25% of patients in each treatment
arm had evaluable questionnaires; for the GHS analysis this equa-
ted to the first 6 months of treatment. This may mean that these
analyses underestimate the overall impact of olaparib treatment
in comparison with placebo, since disease progression and associ-
ated subsequent therapies would be expected to result in
decreased HRQoL. Additional data assessing the psychological
impact of having prolonged disease control (e.g. Brief Illness
Perception Questionnaire or depression scale data) were not col-
lected; however, the possibility of a positive benefit for this popu-
lation of patients who had significantly improved PFS with
maintenance olaparib may be considered.
Conclusions
HRQoL was preserved with olaparib maintenance therapy in
patients with metastatic pancreatic cancer and a gBRCAm whose
disease had not progressed during first-line platinum-based
chemotherapy, with no meaningful difference observed com-
pared with placebo. Results of prespecified end points from the
POLO trial show that maintenance olaparib significantly
Figure 4. Best overall quality of life response for EORTC QLQ-C30 Global Health Status, physical functioning and symptom scales.
Percentages are calculated based on the 86 olaparib-arm patients and 55 placebo-arm patients (54 for the diarrhoea subscale) with available
results. Three patients in each arm (4 placebo arm patients for the diarrhoea subscale) were included in the PRO analysis set, but had no
evaluable baseline or post-baseline results and are excluded from this figure. O, olaparib; P, placebo.
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improved PFS without compromising quality of life, an import-
ant result for patients particularly when considering the cumula-
tive toxicities of standard-of-care chemotherapies.
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Appendix
POLO Investigators
The table lists the principal investigator for each site who partici-
pated in the study.
Country Principal investigator
Australia Lorraine Chantrill,a David Goldstein, Warren Joubert, Nick Pavlakis, Annette Tognela
Belgium Eric Van Cutsem, Frank Van Fraeyenhove, Jean-Luc Van Laethem, Marc Peeters
Canada Neesha Dhani, Petr Kavan, Frederic Lemay
France Antoine Adenis,a Pascal Artru, Nabil Baba-Hamed, Christine Belletier, Meher Ben Abdelghani,a Jean-Frederic Blanc, Christophe Borg,
Romain Coriat, Gael Deplanque,a Roger Faroux, Philippe Follana, Rosine Guimbaud, Farid el Hajbi, Pascal Hammel, Vincent
Hautefeuille, David Malka, Jean-Philippe Metges, David Tougeron, Thomas Walter
Germany Hana Algül, Thomas Ettrich, Ulrich Thorsten Hacker, Elke Hennes, Lutz Jacobasch, Stephan Kanzler, Ursula Pession, Anke Reinacher-
Schick, Christian Scholz, Marianne Sinn, Alexander Stein, Christian Strassburg, Arndt Vogel
Israel Menachem Ben-Shahar,a Ronen Brenner, Ron Epelbaum,a Ravit Geva, Alexander Gluzman, Talia Golan, Efraim Idelevich, Maya
Kolin,a Valeriya Semenisty, Ayelet Shai, Salomon Stemmer, Nirit Yarom
Italy Luigi Celio, Pierfranco Conte, Carlo Garufi, Luca Gianni, Francesco Leonardi, Evaristo Maiello, Mariacristina Di Marco, Michele Milella,
Carmine Pinto,a Daniele Santini, Mario Scartozzi, Giampaolo Tortora,a Vanja Vaccaro, Enrico Vasile
Republic of Korea Ji-Won Kim, Jin-Won Kim,a Do-Youn Oh, Joon Oh Park
The Netherlands Hanneke Wilmink
Spain Rafael Alvarez Gallego, Gema Duran Ogalla, Adelaida Garcia Velasco, Elena Garralda Cabanas,a Carlos Gomez Martin, Carmen
Guillén Ponce, Berta Laquente Saez, Rafael Lopez, Teresa Macarulla, Andres Munoz Martin, Roberto Pazo, Carles Pericay Pijaume,
Javier Rodriguez, Ricardo Yaya-Tur
UK Arvind Arora, David Alan Anthoney, T.R. Jeffrey Evans, Mark Harrison, Daniel Hochhauser, Daniel Palmer, Debashis Sarker, Naureen
Starling, Juan Valle, Lucy Wall
USA Richy Agajanian, James Bearden, Tanios Bekaii-Saab,a Corey Carter, Deirdre Cohen, Alfred DiStefano, Tomislav Dragovich, Samuel
Ejadi, James Ford, Stephen Grabelsky, Michael Hall, Howard Hochster,a Peter Hosein, Milind Javle, Hedy Kindler, Jill Lacy, Daniel
Laheru, Stephen Leong, Maeve Lowery,a Robert Marsh, Anne Noonan, Paul Oberstein, Allyson Ocean, Eileen O’Reilly, David Ryan,
Tara Seery, Somasundaram Subramaniam, David Van Echo,a Andrea Wang-Gillam, Colin Weekes,a Stephen Welch
aFormer principal investigator.
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